Hikma, Celltrion sign monoclonal antibody licensing agreement

(File photo: Jordan News)
Press Release — The multinational Hikma Pharmaceuticals PLC (Hikma) announced a new exclusive licensing agreements with Celltrion Healthcare Co., Ltd. for CT-P43, or ustekinumab, a monoclonal antibody that is a proposed biosimilar to Janssen’s Stelara, according to a press statement.اضافة اعلان

Under the terms of the agreement, Hikma will have exclusive rights to commercialize CT-P43 in its Middle East and North Africa (MENA) markets, and that Celltrion Healthcare will develop, manufacture and supply CT-P43 to Hikma.

The deal will help equip doctors and patients with more treatment options across the region. This agreement also builds on Celltrion Healthcare and Hikma’s existing partnership in MENA, adding another immunology biosimilar to Hikma’s portfolio, a key focus of its strategy.

CT-P43 is an important drug used in the treatment of autoimmune diseases, such as Crohn’s disease and ulcerative colitis.

“We are excited to add CT-P43 to our portfolio, strengthening our offering of biosimilar and innovative biologic products.” said Mazen Darwazah, Hikma’s executive vice chairman and MENA president.

“CT-P43 is the sixth immunology biologic we add to our portfolio in MENA,” he said. “This new addition enables us to increase patients’ access to important specialty products, helping them in their treatment journey for these difficult diseases.”

The press statement said CT-P43 is a biosimilar to Janssen’s Stelara, which is a human monoclonal antibody that inhibits the bioactivity of human IL-12 and IL-23 by preventing shared p40 from binding to the IL-12R 1 receptor protein expressed on the surface of immune cells. IL-12 and IL-23 are involved in inflammatory and immune responses, such as natural killer cell activation, and CD4+ T-cell differentiation and activation.

IL-12 and IL-23 have been implicated as important contributors to the chronic inflammation that is a hallmark of Crohn’s disease and ulcerative colitis, among many other autoimmune diseases.

Read more Business
Jordan News